This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… mais…
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
Springer.com
new in stock. Custos de envio:zzgl. Versandkosten. (EUR 0.00) Details...
(*) Livro esgotado significa que o livro não está disponível em qualquer uma das plataformas associadas buscamos.
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… mais…
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
BookDepository.com
Custos de envio:Versandkostenfrei. (EUR 0.00) Details...
(*) Livro esgotado significa que o livro não está disponível em qualquer uma das plataformas associadas buscamos.
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challe… mais…
This book provides the reader with broad perspectives and breadth of knowledge on current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. The book is divided into 4 parts. The first part begins with the current technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. The second part deals with the use proteomics in cell signaling. At the present, the pharmaceutical and biotechnology industries have many potentially useful small molecule inhibitors of many pathways important in cancer that have yet to be taken to clinical trials. Understanding protein-protein interaction and posttranslational modifications through proteomics will likely make it much more feasible to do effective clinical trials of these small molecules alone and in combinations to overcome drug resistance and improve patient care. The third part of the book moves from signaling to actual clinical applications of proteomics in cancer therapy. Case studies in may tumor types are provided to show the feasibility of generating the critical information needed to individualization of therapy in cancer patients. The final part of the book provides in depth information on annotating the human proteome and the role of Food and Drug Administration (FDA) in regulating the use of proteomics in cancer therapy. To functionally annotate the human proteome, the Swiss Institute for Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) initiated a major effort to distribute to the scientific community highly integrated information on human protein sequences. This initiative, which is called the Human Proteomics Initiative (HPI) aims to provide for each known human protein a wealth of information that include the description of its function, domain and protein family classification, subcellular location, posttranslational modifications, variants and similarities to other proteins. Integration of bioinformatics into clinical application of proteomics in cancer therapy is outlined as well as regulations and policy of commercial application of proteomics in patient care. Books > Biomedicine Soft cover, Springer Shop<
new in stock. Custos de envio:zzgl. Versandkosten. (EUR 0.00)
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in canc… mais…
Paperback, [PU: Humana Press Inc.], It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics., Oncology<
1Como algumas plataformas não transmitem condições de envio e estas podem depender do país de entrega, do preço de compra, do peso e tamanho do item, de uma possível adesão à plataforma, de uma entrega direta pela plataforma ou através de um fornecedor terceirizado (Marketplace), etc., é possível que os custos de envio indicados pela terralivro não correspondam aos da plataforma ofertante.
Dados bibliográficos do melhor livro correspondente
This book covers current topics related to the use of proteomic strategies in cancer therapy as well as anticipated challenges that may arise from its application in daily practice. It details current technologies used in proteomics, examines the use proteomics in cell signaling, presents clinical applications of proteomics in cancer therapy, and looks at the role of the FDA in regulating the use of proteomics.
Dados detalhados do livro - Cancer Proteomics: From Bench to Bedside
EAN (ISBN-13): 9781617378072 ISBN (ISBN-10): 1617378070 Livro de capa dura Livro de bolso Ano de publicação: 2010 Editor/Editora: SPRINGER VERLAG GMBH 276 Páginas Peso: 0,399 kg Língua: eng/Englisch
Livro na base de dados desde 2012-11-02T17:05:20-02:00 (Sao Paulo) Página de detalhes modificada pela última vez em 2021-09-19T12:24:38-03:00 (Sao Paulo) Número ISBN/EAN: 9781617378072
Número ISBN - Ortografia alternativa: 1-61737-807-0, 978-1-61737-807-2 Ortografia alternativa e termos de pesquisa relacionados: Autor do livro: daoud
Dados da editora
Autor: Sayed S. Daoud Título: Cancer Drug Discovery and Development; Cancer Proteomics - From Bench to Bedside Editora: Humana; Humana Press 264 Páginas Ano de publicação: 2010-12-09 Totowa; NJ; US Impresso / Feito em Língua: Inglês 219,99 € (DE)
BC; Hardcover, Softcover / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Bioinformatics; Cancer Research; Carcinom; Oncology; Proteomics; Translation; classification; diagnostics; proteins; Cancer Biology; Protein Biochemistry; Oncology; Biochemie; BB
Proteomics Technologies.- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses.- Cell Signaling Proteomics.- Integration of Genomics and Proteomics in Dissecting p53 Signaling.- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy.- Tumor Proteomics.- Oncoproteomics for Personalized Management of Cancer.- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors.- Insight on Renal Cell Carcinoma Proteome.- Proteomics in Lung Cancer.- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia.- New Tumor Biomarkers.- Bioinformatics and Regulatory Aspects of Proteomics.- Annotating the Human Proteome.- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
Outros livros adicionais, que poderiam ser muito similares com este livro: